AXSM
Income statement / Annual
Last year (2024), Axsome Therapeutics, Inc.'s total revenue was $385.69 M,
an increase of 42.53% from the previous year.
In 2024, Axsome Therapeutics, Inc.'s net income was -$287.22 M.
See Axsome Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$385.69 M |
$270.60 M |
$50.04 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$33.30 M
|
$26.07 M
|
$5.20 M
|
$0.00
|
$0.00
|
$37.33 K
|
$48.94 K
|
$42.56 K
|
$20.48 K
|
$3.54 K
|
| Gross Profit |
$352.39 M
|
$244.54 M
|
$44.84 M
|
$0.00
|
$0.00
|
-$37.33 K
|
-$48.94 K
|
-$42.56 K
|
-$20.48 K
|
-$3.54 K
|
| Gross Profit Ratio |
0.91
|
0.9
|
0.9
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$187.08 M
|
$97.94 M
|
$57.95 M
|
$58.06 M
|
$70.24 M
|
$53.65 M
|
$23.50 M
|
$19.96 M
|
$21.20 M
|
$6.78 M
|
| General & Administrative Expenses |
$310.16 M
|
$222.82 M
|
$0.00
|
$66.65 M
|
$28.90 M
|
$13.60 M
|
$9.35 M
|
$7.21 M
|
$6.34 M
|
$2.42 M
|
| Selling & Marketing Expenses |
$101.20 M
|
$100.30 M
|
$0.00
|
-$205.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$411.36 M
|
$323.12 M
|
$159.25 M
|
$66.65 M
|
$28.90 M
|
$13.60 M
|
$9.35 M
|
$7.21 M
|
$6.34 M
|
$2.42 M
|
| Other Expenses |
$34.52 M
|
$55.29 M
|
$7.44 M
|
$0.00
|
-$53.58 K
|
-$139.45 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$632.95 M
|
$476.36 M
|
$224.64 M
|
$124.71 M
|
$99.14 M
|
$67.11 M
|
$32.85 M
|
$27.16 M
|
$27.54 M
|
$9.20 M
|
| Cost And Expenses |
$666.26 M
|
$502.43 M
|
$229.84 M
|
$124.71 M
|
$99.09 M
|
$67.11 M
|
$32.63 M
|
$27.16 M
|
$27.54 M
|
$9.20 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.57 M
|
$1.24 M
|
$0.00
|
$0.00
|
$0.00
|
$914.95 K
|
| Interest Expense |
$6.57 M
|
$6.45 M
|
$7.34 M
|
$5.70 M
|
$2.57 M
|
$1.24 M
|
$1.13 M
|
$1.34 M
|
$132.42 K
|
$914.95 K
|
| Depreciation & Amortization |
$7.96 M
|
$6.83 M
|
$4.40 M
|
$76.00 K
|
$77.72 K
|
$37.33 K
|
$48.94 K
|
$42.56 K
|
$20.48 K
|
$3.54 K
|
| EBITDA |
-$272.60 M |
-$224.99 M |
-$175.40 M |
-$124.63 M |
-$100.31 M |
-$67.21 M |
-$32.58 M |
-$27.77 M |
-$27.52 M |
-$9.19 M |
| EBITDA Ratio |
-0.71
|
-0.83
|
-3.51
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.73
|
-0.86
|
-3.59
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$6.57 M
|
-$6.45 M
|
-$7.34 M
|
-$5.70 M
|
-$3.76 M
|
-$1.10 M
|
$1.66 M
|
-$1.78 M
|
$341.86 K
|
-$1.36 M
|
| Income Before Tax |
-$287.13 M
|
-$238.28 M
|
-$187.13 M
|
-$130.40 M
|
-$102.90 M
|
-$68.35 M
|
-$30.97 M
|
-$28.94 M
|
-$27.20 M
|
-$10.56 M
|
| Income Before Tax Ratio |
-0.74
|
-0.88
|
-3.74
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$85.00 K
|
$960.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.36 M
|
| Net Income |
-$287.22 M
|
-$239.24 M
|
-$187.13 M
|
-$130.40 M
|
-$102.90 M
|
-$68.35 M
|
-$30.97 M
|
-$28.94 M
|
-$27.20 M
|
-$12.21 M
|
| Net Income Ratio |
-0.74
|
-0.88
|
-3.74
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-5.99 |
-5.27 |
-4.6 |
-3.47 |
-2.83 |
-2.05 |
-1.15 |
-1.27 |
-1.42 |
-0.88 |
| EPS Diluted |
-5.99 |
-5.27 |
-4.6 |
-3.47 |
-2.83 |
-2.05 |
-1.15 |
-1.27 |
-1.42 |
-0.88 |
| Weighted Average Shares Out |
$47.91 M
|
$45.43 M
|
$40.66 M
|
$37.62 M
|
$37.21 M
|
$34.02 M
|
$26.88 M
|
$22.76 M
|
$19.15 M
|
$11.95 M
|
| Weighted Average Shares Out Diluted |
$47.91 M
|
$45.43 M
|
$40.66 M
|
$37.62 M
|
$37.21 M
|
$34.02 M
|
$26.88 M
|
$22.76 M
|
$19.15 M
|
$11.95 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
